Cargando…

Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study

BACKGROUND: While booster vaccinations clearly reduce the risk of severe Coronavirus Disease 2019 (COVID-19) and death, the impact of boosters on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections has not been fully characterized: Doing so requires understanding their impact on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Jiayue, Cazer, Casey L., Clarkberg, Marin E., Henderson, Shane G., Lee, Scarlett E., Meredith, Genevive R., Osman, Marwan, Shmoys, David B., Frazier, Peter I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876273/ https://www.ncbi.nlm.nih.gov/pubmed/36626376 http://dx.doi.org/10.1371/journal.pmed.1004153

Ejemplares similares

Routine Surveillance and Vaccination on a University Campus During the Spread of the SARS-CoV-2 Omicron Variant
por: Meredith, Genevive R., et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
por: Wang, Lindsey, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Antimicrobial resistance among canine enterococci in the northeastern United States, 2007–2020
por: Osman, Marwan, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance
por: Sirison, Kanchanok, et al.
Publicado: (2023)

Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study
por: Mimura, Wataru, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan
por: Tomioka, Kimiko, et al.
Publicado: (2023)

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination
por: Habermann, Elisa, et al.
Publicado: (2022)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

EPH257 Public Health Impact of UK COVID-19 Booster Vaccination during Omicron Predominance
por: Mendes, D., et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2022)

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase
por: Aggarwal, Neil R., et al.
Publicado: (2023)

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2
por: Swart, Maarten, et al.
Publicado: (2023)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
por: Tuan, Jessica J., et al.
Publicado: (2023)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Modeling for COVID-19 college reopening decisions: Cornell, a case study
por: Frazier, Peter I., et al.
Publicado: (2022)

Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France
por: Tamandjou, Cynthia, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster
por: Amir, Ofra, et al.
Publicado: (2023)

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5
por: Molina, Kyle C., et al.
Publicado: (2023)

Exploratory analysis of SARS-CoV-2 omicron variant and its subvariant propagation: global predominance of BA.1*, BA.2*, BA.5*, BE.1*, and BQ.1*
por: Muthusami, Rathinasamy, et al.
Publicado: (2023)

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2023)

SARS-CoV-2 Incubation Period during the Omicron BA.5–Dominant Period in Japan
por: Ogata, Tsuyoshi, et al.
Publicado: (2023)

EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA.1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA.4/BA.5 Dominance
por: Maschio, M, et al.
Publicado: (2022)

Risk Factors Related to COVID-19 Reinfection and Fatality During the Omicron (BA.1/BA.2) Period in Korea
por: Lee, Ju Hee, et al.
Publicado: (2023)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Clinical characteristics of COVID-19 in hospitalized children during the Omicron variant predominant period
por: Shoji, Kensuke, et al.
Publicado: (2022)

Shorter Incubation Period among COVID-19 Cases with the BA.1 Omicron Variant
por: Tanaka, Hideo, et al.
Publicado: (2022)

Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort
por: Itamochi, Masae, et al.
Publicado: (2023)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
por: Winokur, Patricia, et al.
Publicado: (2023)

Prioritisation of COVID-19 boosters in the omicron era
por: Irving, Stephanie A, et al.
Publicado: (2022)

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
por: Wei, Jia, et al.
Publicado: (2023)

High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster( )
por: Guirakhoo, Farshad, et al.
Publicado: (2022)

Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominancy
por: Miyauchi, Shunsuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1hek2abnrbca1djvmdbg0858rl